http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Regeneron (REGN) Reports Dupixent Granted European Commission Approval for Adolescents with Moderate-to-Severe Atopic Sermatitis
-
Regeneron (REGN) Highlights Positive Topline Results in Phase 3 Trial
-
Sanofi : Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis
-
Dupixent® (dupilumab) Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years with Severe Atopic Dermatitis
-
Sanofi : Dupixent® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis
-
Dupixent® (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis
-
Regeneron Announces the 2019 Winners of the Regeneron Prize for Creative Innovation
-
Regeneron to Report Second Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on August 6, 2019
-
Sanofi (SNY) announces Libtayo approved for advanced cutaneous squamous cell carcinoma in European Union
-
Libtayo® (cemiplimab) Approved for Advanced Cutaneous Squamous Cell Carcinoma in the European Union
-
Sanofi : Libtayo® (cemiplimab) approved for advanced cutaneous squamous cell carcinoma in the European Union
-
Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents
-
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (SNY) Report CHMP Approval of Dupixent (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents
-
Regeneron (REGN), Sanofi Announce FDA Approval of Dupixent for Chronic Rhinosinusitis with Nasal Polyposis
-
FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis
-
Sanofi : FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis
-
FDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis
-
Regeneron (REGN), Sanofi (SNY) Report Positive Topline Phase 2 Results for IL-33 Antibody in Asthma
-
Sanofi and Regeneron announce positive topline Phase 2 results for IL-33 antibody in asthma
-
Regeneron and Sanofi Announce Positive Topline Phase 2 Results for IL-33 Antibody in Asthma
-
Regeneron (REGN) CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with R/R B-NHL, including in CAR-T Failures
-
Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures
-
Regeneron Announces Upcoming Investor Conference Presentation
-
Regeneron (REGN) Says Updated Libtayo Results Reinforce Durable and Substantial Response Rates in Advanced CSCC
-
Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
-
FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy
-
Regeneron (REGN) Announces FDA Approves EYLEA Injection for Diabetic Retinopathy
-
FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy
-
Sanofi (SNY), Regeneron (REGN) Report Dupixent (dupilumab) Approved for Severe Asthma by European Commission
-
Sanofi : Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
-
Sanofi : Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
-
Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
-
Regeneron Reports First Quarter 2019 Financial and Operating Results
-
Regeneron Announces Upcoming Investor Conference Presentations
-
Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization
-
Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization
-
FDA Approves Praluent® (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization
-
Regeneron (REGN) Announces CHMP Issues Positive Opinion for Libtayo (cemiplimab) in Advanced Cutaneous Squamous Cell Carcinoma
-
CHMP issues positive opinion for Libtayo in advanced cutaneous squamous cell carcinoma (REGN) (SNY)
-
CHMP issues positive opinion for Libtayo® (cemiplimab) in advanced cutaneous squamous cell carcinoma
-
CHMP issues positive opinion for Libtayo® (cemiplimab) in advanced cutaneous squamous cell carcinoma
-
CHMP Issues Positive Opinion for Libtayo® (cemiplimab) in Advanced Cutaneous Squamous Cell Carcinoma
-
Regeneron to Report First Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2019
-
Alnylam (ALNY), Regeneron (REGN) Announce Pact on RNAi Therapeutics Focused on Ocular and CNS Diseases; Regeneron to Make Payment of $400M Upfront and Purchase Stock at $90/Share
-
Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
-
Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
-
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
-
Regeneron (REGN) says Praluent now approved in EU to reduce risk of cardiovascular events in patients with established cardiovascular disease
-
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
-
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
